Classical Swine Fever Virus Vaccines

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Veterinary Vaccines".

Deadline for manuscript submissions: 31 July 2026 | Viewed by 127

Special Issue Editors


E-Mail Website
Guest Editor
Institut de Recerca i Technologia Agroalimentaries, Caldes de Montbui, Spain
Interests: veterinary virology; molecular biology; diagnosis; PCR; viruses; swine virus; Pestivirus; classical swine fever virus; viral evolution; immune response; viral persistence; pathogenesis

E-Mail Website
Guest Editor
Swine and Poultry Infectious Diseases Research Center (CRIPA), Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, QC J2S 2M2, Canada
Interests: virology; veterinary microbiology; innate immune response; animal model; pig; vaccines; mucosal immunology; respiratory and intestinal infectious diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Classical swine fever (CSF) is, without any doubt, one of the most devastating viral infectious diseases affecting the members of the Suidae family, which causes a severe impact on the global economy. The reemergence of CSF virus (CSFV) in several countries in America and Asia, and sporadic outbreaks in Europe shed light on the serious concern that a potential global reemergence of this disease represents. The negative aspects related to the application of mass stamping-out policies, including elevated costs and ethical issues, point out vaccination as the main control measure against future outbreaks. However, despite the implemented efforts by many government authorities to control and eradicate CSF from national pig populations, the disease remains endemic in Asia, some countries in Europe, the Caribbean, and South America.

Hence, it is imperative that the scientific community continue active research into more effective vaccines against CSFV capable of eliciting robust humoral and cellular immunities, as well as the ability to differentiate vaccinated from unvaccinated animals.

This Special Issue will focus on the advances in the development of novel vaccines and strategies against CSFV, looking to gather the current knowledge in marker vaccines with DIVA capability and molecular characterization of escaping variants for this viral agent. All papers, including original research articles and reviews, are welcome.

We look forward to receiving your contributions.

Dr. Liani Coronado
Dr. François Meurens
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • classical swine fever
  • vaccine
  • DIVA concept
  • discriminatory tool for DIVA vaccine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 2409 KB  
Article
Immunogenicity and Contraceptive Potential of a Classical Swine Fever Viral Vector Live Vaccine Strain Containing Pig Gonadotropin-Releasing Hormone
by Dong-Jun An, Ji-Hee Shin, SeEun Choe, Young-Hyeon Lee, Min-Kyung Jang, Byung-Hyun An, Gyu-Nam Park, Yun-Sang Cho and Kyung-Soo Chang
Vaccines 2025, 13(10), 1048; https://doi.org/10.3390/vaccines13101048 - 12 Oct 2025
Abstract
Background: Classical swine fever virus (CSFV) is a highly contagious and fatal disease in pigs and wild boars. While hunting and bait vaccination are effective for CSFV eradication, additional strategies are needed to control wild boar populations. This study aimed to develop an [...] Read more.
Background: Classical swine fever virus (CSFV) is a highly contagious and fatal disease in pigs and wild boars. While hunting and bait vaccination are effective for CSFV eradication, additional strategies are needed to control wild boar populations. This study aimed to develop an oral vaccine, Flc-LOM-GnRHx3, by inserting gonadotropin-releasing hormone (GnRH) epitopes into the Flc-LOM clone. Methods: The Flc-LOM-GnRHx3 strain was rescued from CPK cells and propagated to high titers in MDBK cells. Male boars (20 weeks old) received three doses (105.0 TCID50/ml/dose) of Flc-LOM-GnRHx3 either orally or intramuscularly at 2-week intervals. Anti-CSFV E2 antibodies were detected via immunofluorescence and Western blotting. Results: Both vaccination routes induced anti-GnRH antibodies and reduced testosterone levels. Testis size and weight were slightly lower than controls, with seminiferous tubule and spermatid deformities observed in 52.5% of intramuscularly vaccinated pigs and 20.8% of orally vaccinated pigs. Conclusions: Flc-LOM-GnRHx3 demonstrates potential as a dual-function oral vaccine that can eradicate CSFV and impair reproductive capacity in wild boars, offering a novel approach for integrated disease control and population management. Full article
(This article belongs to the Special Issue Classical Swine Fever Virus Vaccines)
Show Figures

Figure 1

Back to TopTop